-
In patients with ALI/ARDS from pulmonary and extrapulmonary causes, receiving mechanical ventilation with low tidal volumes and high PEEP, short-term effects of recruitment maneuvers as conducted in this study are variable.
-
-
The carotid artery stent system from Cordis Endovascular (Miami Lakes, Florida) is one step closer to approval by the FDA. At a meeting on April 21, the Circulatory System Devices Panel of the agencys Center for Devices and Radiological Health recommended approval of the premarket approval (PMA) application for the Cordis Carotid System, with conditions, by a narrow 6-to-5 vote.
-
Gary Stickel has joined Abiomed (Danvers, Massachusetts) as vice president of human resources and development. Stickel previously was vice president of human resources at Segue Software. Abiomed is a manufacturer of devices designed to assist or replace the pumping function of the failing heart.
-
Alliance Medical (Phoenix, Arizona), a reprocessor of single-use medical devices (SUDs), said VHA (Irving, Texas), a cooperative of community-owned healthcare organizations, has renewed a three-year contract with Alliance.
-
Arrhythmia Research Technology (ART; Fitchburg, Massachusetts) said its wholly owned subsidiary, Micron Products, has completed the purchase of substantially all of the operating assets of privately held New England Molders (NEMI; Shrewsbury, Massachusetts).
-
Arrow International (Reading, Pennsylvania) said last month that it plans to defer a U.S. clinical trial of its current iteration of the LionHeart Left Ventricular Assist System (LVAS) for a destination therapy indication, saying it prefers to see how the next generation of the device, which has a smaller battery and other system enhancements, fares in the European market, where it was approved via a CE mark last November.
-
Presenters revealed some stunning data in coronary and peripheral revascularization during a press conference on late-breaking trials at the American College of Cardiologys (ACC; Bethesda, Maryland) annual scientific sessions in early March. The presentations at the Ernest N. Morial Convention Center included results from the three iterations of the ARCHeR (Acculink for Revascularization of Carotids in High-Risk Patients) trial, which is focused on treatment of carotid artery disease.
-
Early detection and rapid treatment is one of the most effective strategies available to physicians for improving outcomes of patients with myocardial infarction. A variety of technologies are under development that are intended to improve the ability to detect a heart attack rapidly, while others are designed to help minimize the adverse consequences of an acute coronary event using novel modalities to support the heart or preserve heart tissue.
-
Sulfonamide Antibiotics and Sulfonamide Nonantibiotics; Autoantibodies
Before Onset of SLE; Prevention of VTE with Ximelagatran; Combined
Levothyroxine Plus Liothyronine Compared to Levothyroxine Alone in
Primary Hypothyroidism; Specific Site Involvement in Fixed Drug
Eruption; Anticoagulation Therapy for Stroke Prevention in Patients
with Atrial Fibrillation
